# Emerging Mechanisms of Abdominal Aortic Aneurysm

**Authors:** Botao Zhu, Y. Eugene Chen, Yanhong Guo

PMC · DOI: 10.1007/s11883-026-01392-5 · 2026-01-30

## TL;DR

This paper reviews recent discoveries about the complex biological processes behind abdominal aortic aneurysms and how they could lead to new treatments.

## Contribution

The paper highlights new insights into cellular interactions and systemic factors in AAA pathogenesis and identifies novel therapeutic targets.

## Key findings

- Single-cell studies reveal cellular heterogeneity and dynamic interactions in aneurysmal tissue.
- Immune cells like macrophages and neutrophils drive inflammation and matrix degeneration in AAA.
- Systemic factors such as gut microbiota and sex hormones influence AAA progression.

## Abstract

Abdominal aortic aneurysm (AAA) is a progressive and often fatal vascular disease for which effective pharmacological therapies are lacking. This review synthesizes recent mechanistic advances in AAA pathogenesis and evaluates their translational significance for therapeutic development.

Single-cell and spatial transcriptomic findings have delineated marked cellular heterogeneity within aneurysmal tissue, revealing dynamic interactions among vascular and immune cell populations. Vascular smooth muscle cell phenotypic modulation and programmed cell death compromise aortic wall integrity, while endothelial dysfunction promotes leukocyte recruitment and mediates early vascular responses. Infiltrating macrophages, neutrophils, and adaptive immune cells orchestrate chronic inflammation and extracellular matrix degeneration, whereas eosinophils and regulatory T cells exert context-dependent protective effects. Local factors, including intraluminal thrombus and perivascular adipose tissue, as well as systemic modulators such as dyslipidemia, gut microbiota, and sex hormones, further shape disease initiation and progression. These mechanistic insights have identified novel therapeutic targets, including inhibitors of regulated cell death, immunomodulatory agents, lipid-lowering interventions, and microbiome-directed strategies, and potential biomarkers for earlier diagnosis and improved risk stratification.

Emerging mechanistic insights have highlighted the complex interplay among vascular cells, immune cells, the local microenvironment, and systemic modulators in the pathogenesis of AAA. Integrating mechanistic insights with translational research will be crucial in developing targeted interventions that pave the way for effective AAA therapies.

## Linked entities

- **Diseases:** abdominal aortic aneurysm (MONDO:0005350)

## Full-text entities

- **Genes:** GP6 (glycoprotein VI platelet) [NCBI Gene 51206] {aka BDPLT11, GPIV, GPVI}, CAT (catalase) [NCBI Gene 847], Ltb (lymphotoxin B) [NCBI Gene 16994] {aka LTbeta, Tnfc, Tnfsf3, Tnlg1c, p33}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Lamp1 (lysosomal-associated membrane protein 1) [NCBI Gene 16783] {aka CD107a, LGP-120, LGP-A, Lamp-1, P2B, Perk}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, MIR19B1 (microRNA 19b-1) [NCBI Gene 406980] {aka C13orf25, MIR19B, MIRH1, MIRHG1, MIRN19B1, miR-19b-1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, GSDMD (gasdermin D) [NCBI Gene 79792] {aka DF5L, DFNA5L, FKSG10, GSDMDC1}, Ltbr (lymphotoxin B receptor) [NCBI Gene 17000] {aka LTbetaR, Ltar, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP}, P2RY2 (purinergic receptor P2Y2) [NCBI Gene 5029] {aka HP2U, P2RU1, P2U, P2U1, P2UR, P2Y2}, NOS3 (nitric oxide synthase 3) [NCBI Gene 397557] {aka EC-NOS, NOS, NOSIII, cNOS, eNOS}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, ANGPTL3 (angiopoietin like 3) [NCBI Gene 27329] {aka ANG-5, ANGPT5, ANL3, FHBL2}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, Fam3c (FAM3 metabolism regulating signaling molecule C) [NCBI Gene 27999] {aka D6Wsu176e, Ilei}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, LOX (lysyl oxidase) [NCBI Gene 100525278], DAPK2 (death associated protein kinase 2) [NCBI Gene 23604] {aka DRP-1, DRP1}, Mmp12 (matrix metallopeptidase 12) [NCBI Gene 17381] {aka MME, Mmel}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, Smarcd3 (SWI/SNF related BAF chromatin remodeling complex subunit D3) [NCBI Gene 66993] {aka 1500001J14Rik, 2210409C08Rik, BAF60C}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, Ctsd (cathepsin D) [NCBI Gene 13033] {aka CD, CatD}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) [NCBI Gene 8869] {aka SATI, SIAT9, SIATGM3S, SPDRS, ST3Gal V, ST3GalV}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, P2RX7 (purinergic receptor P2X 7) [NCBI Gene 5027] {aka P2X7}, PDCD1 (programmed cell death 1) [NCBI Gene 100533201], MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 397391] {aka MMP-2}, STK26 (serine/threonine kinase 26) [NCBI Gene 51765] {aka MASK, MST4}, Irf3 (interferon regulatory factor 3) [NCBI Gene 54131] {aka C920001K05Rik, IRF-3}, APOC3 (apolipoprotein C3) [NCBI Gene 345] {aka APOCIII, Apo-C3, ApoC-3}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 100620501], Ccr2 (C-C motif chemokine receptor 2) [NCBI Gene 12772] {aka Cc-ckr-2, Ccr2a, Ccr2b, Ckr2, Ckr2a, Ckr2b}, TAGLN (transgelin) [NCBI Gene 6876] {aka SM22, SM22-alpha, SMCC, TAGLN1, TGLN, WS3-10}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, Trem1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 58217], Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, Notch2 (notch 2) [NCBI Gene 18129] {aka N2}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, ODC1 (ornithine decarboxylase 1) [NCBI Gene 4953] {aka BABS, NEDBA, NEDBIA, ODC}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, Gpnmb (glycoprotein (transmembrane) nmb) [NCBI Gene 93695] {aka DC-HIL, Dchil, ipd}, Ctsc (cathepsin C) [NCBI Gene 13032] {aka CatC, DPP1, DPPI}
- **Diseases:** Chronic Inflammation (MESH:D007249), kidney injury (MESH:D007674), Dyslipidemia (MESH:D050171), hypercholesterolemia (MESH:D006937), Endothelial dysfunction (MESH:D014652), myocardial infarction (MESH:D009203), chronic kidney disease (MESH:D051436), hypertriglyceridemia (MESH:D015228), Endothelial NOS3 (MESH:D005642), necrotic (MESH:D009336), vascular injury (MESH:D057772), coronary artery disease (MESH:D003324), aorta (MESH:D000784), rupture (MESH:D012421), NET (MESH:C536657), deaths (MESH:D003643), cardiovascular diseases (MESH:D002318), aortic (MESH:D001018), atherogenic (MESH:D050197), AAA lesions (MESH:D017544), atrial fibrillation (MESH:D001281), aortic aneurysm (MESH:D001014), hemorrhage (MESH:D006470), hypercholesterolemic (MESH:D006938), AAAs (MESH:C536008), aortic dilation (MESH:D002311), aneurysm (MESH:D000783), hypertension (MESH:D006973), renal failure (MESH:D051437), ILT (MESH:D013927), Mitochondrial Dysfunction (MESH:D028361), hyperlipidemia (MESH:D006949), autoimmune (MESH:D001327), aortic rupture (MESH:D001019)
- **Chemicals:** norepinephrine (MESH:D009638), TG (MESH:D014280), difluoromethylornithine (MESH:D000518), phospholipids (MESH:D010743), TGs (MESH:C026285), cholesterol (MESH:D002784), ATP (MESH:D000255), ganglioside (MESH:D005732), Cryptotanshinone (MESH:C037886), CaCl2 (MESH:D002122), polyunsaturated fatty acids (MESH:D005231), TC (MESH:D013667), iron (MESH:D007501), nicotine (MESH:D009538), TMAO (MESH:C005855), putrescine (MESH:D011700), ticagrelor (MESH:D000077486), NO (MESH:D009569), Fe3O4 (-), Lipid (MESH:D008055)
- **Species:** gut metagenome (species) [taxon 749906], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Salvia miltiorrhiza (Chinese salvia, species) [taxon 226208]
- **Mutations:** JAK2V617F
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), VSMC — Homo sapiens (Human), Finite cell line (CVCL_4009)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12858482/full.md

---
Source: https://tomesphere.com/paper/PMC12858482